

Just in Time Activation Scheme



PemOla

A Phase 2 Single Arm trial, PemOla evaluates the role of immunotherapy in a subgroup of patients with metastatic pancreatic adenocarcinoma

What is it?

PemOla is the first trial to utilise the Just in Time (JiT) Activation Scheme. Given the rarity of this participant group, the JiT scheme allows for the opportunity for sites to recruit an eligible participant at short notice, as the JiT process begins when a potential participant is identified, and not before.

Benefits:

- Minimal impact on NHS organisations which set up through JiT after participant identification.
- Study delivery activities are straightforward and do not require additional activities that would not ordinarily be delivered as part of care.
- No special or specific arrangements required and no excess treatment costs.
- The workload associated with the trial shouldn't impact on wider research or clinical delivery at sites.

Next Steps:

Complete this [short questionnaire](#) to help us understand if the suggested Just in Time timeframes are feasible.

If you have a potentially eligible participant, please contact the PemOla trial team at cuh.pemola@nhs.net copying in your R&D department and the RRDN Study Support Services Team (or equivalent in Devolved Nations).

For More Information:

For queries or feedback related to the Just in Time Scheme, please contact: Catherine.Fleetwood-Walker@nihr.ac.uk

Details of the PemOla Trial can be found on their dedicated website:

PemOla